Wall Street analyst estimates for Edwards Lifesciences Corporation (EW): consensus price target, buy/hold/sell recommendations and forecasts for revenue and EPS for the upcoming fiscal years.
Edwards Lifesciences Corporation is a global medical technology firm specializing in sophisticated products and technologies for structural heart conditions, alongside critical care and surgical patient monitoring. With operations spanning the United States, Europe, Japan, and various international territories, the company offers a comprehensive suite of solutions.
Revenue and EPS estimates
| Fiscal year | Revenue (average) | Revenue (low – high) | EPS (average) | Analysts |
|---|---|---|---|---|
| 2026E | $6.8B | $6.7B – $6.8B | $3.00 | 17 |
| 2027E | $7.4B | $7.2B – $7.5B | $3.39 | 17 |
| 2028E | $8.2B | $7.9B – $8.6B | $3.81 | 8 |
Figures in USD · consensus as of November 1, 2026
Analyst Consensus
| Strong Buy | 0 |
| Buy | 33 |
| Hold | 16 |
| Sell | 0 |
| Strong Sell | 0 |
| Total analysts | 49 |
| Avg rating (−2 sell to +2 buy) | 0.67 |
Recent Earnings Surprises
| Date | EPS Actual | EPS Est. | vs Est. |
|---|---|---|---|
| 2026-11-04 | $0.74 | ||
| 2026-07-23 | $0.78 | $0.74 | +5.0% |
| 2026-04-23 | $0.78 | $0.73 | +7.0% |
| 2026-02-10 | $0.58 | $0.62 | -6.1% |
| 2025-10-30 | $0.67 | $0.60 | +12.4% |
| 2025-07-24 | $0.67 | $0.62 | +7.4% |
| 2025-04-23 | $0.64 | $0.60 | +7.4% |
| 2025-02-11 | $0.59 | $0.55 | +7.1% |
Valuation Ratios
| P/E Ratio | 53.60 |
| Price / Book | 5.06 |
| Dividend Yield | 0.00% |
Income Statement (10y)
| Year | 2001 | 2002 | 2003 | 2004 | 2005 | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $692.0M | $704.0M | $860.5M | $931.5M | $997.9M | $1.04B | $1.09B | $1.24B | $1.32B | $1.45B | $1.68B | $1.90B | $2.05B | $2.32B | $2.49B | $2.96B | $3.44B | $3.72B | $4.35B | $4.39B | $5.23B | $5.38B | $5.01B | $5.44B | $6.07B |
| Cost of Revenue | $324.0M | $299.1M | $359.4M | $370.2M | $374.6M | $383.3M | $381.3M | $408.9M | $404.1M | $410.1M | $460.8M | $506.8M | $543.9M | $631.2M | $684.3M | $805.8M | $882.9M | $922.1M | $1.16B | $1.10B | $1.23B | $1.17B | $1.04B | $1.12B | $1.33B |
| Gross Profit | $368.0M | $404.9M | $501.1M | $561.3M | $623.3M | $653.7M | $709.8M | $828.8M | $917.3M | $1.04B | $1.22B | $1.39B | $1.50B | $1.69B | $1.81B | $2.16B | $2.55B | $2.80B | $3.19B | $3.29B | $4.01B | $4.22B | $3.97B | $4.32B | $4.74B |
| Research & Development | $55.0M | $65.2M | $72.8M | $87.0M | $99.0M | $114.2M | $122.3M | $139.2M | $175.5M | $204.4M | $246.3M | $291.3M | $323.0M | $346.5M | $383.1M | $442.2M | $552.6M | $622.2M | $752.7M | $760.7M | $903.1M | $945.2M | $962.9M | $1.05B | $1.08B |
| Selling, General & Admin | $203.0M | $227.9M | $289.9M | $319.9M | $348.7M | $376.0M | $418.0M | $480.6M | $508.8M | $550.0M | $642.4M | $704.8M | $745.6M | $858.0M | $850.4M | $900.2M | $989.7M | $1.09B | $1.24B | $1.23B | $1.49B | $1.57B | $1.58B | $1.79B | $2.09B |
| Operating Expenses | $344.0M | $352.8M | $362.7M | $406.9M | $447.7M | $490.2M | $540.3M | $619.8M | $684.3M | $754.4M | $888.7M | $996.1M | $1.07B | $1.20B | $1.23B | $1.34B | $1.54B | $1.71B | $1.99B | $1.99B | $2.40B | $2.51B | $2.55B | $2.94B | $3.10B |
| Operating Income | $24.0M | $52.1M | $138.4M | $154.4M | $175.6M | $163.5M | $169.5M | $209.0M | $233.0M | $282.5M | $329.1M | $396.7M | $433.0M | $487.2M | $575.9M | $815.5M | $1.01B | $1.09B | $1.20B | $1.30B | $1.61B | $1.70B | $1.43B | $1.38B | $1.64B |
| EBITDA | $81.1M | $92.5M | $184.0M | $100.0M | $185.2M | $239.6M | $213.7M | $227.2M | $365.8M | $327.1M | $344.7M | $452.8M | $589.8M | $1.23B | $706.6M | $827.1M | $1.14B | $872.2M | $1.28B | $1.05B | $1.86B | $1.93B | $1.53B | $1.72B | $1.43B |
| Interest Expense | $23.0M | $11.5M | $13.2M | $14.2M | $12.3M | $10.5M | $9.1M | $7.2M | $2.7M | $2.4M | $3.1M | $4.4M | $5.8M | $21.6M | $18.4M | $18.0M | $23.2M | $33.4M | $27.3M | $22.2M | $24.8M | $26.2M | $17.6M | $19.8M | 0 |
| Pre-tax Income | -$9.0M | $56.0M | $92.8M | $30.1M | $116.7M | $172.3M | $149.8M | $164.4M | $304.4M | $268.2M | $283.6M | $391.1M | $515.3M | $1.14B | $622.4M | $737.9M | $1.03B | $761.4M | $1.17B | $916.7M | $1.70B | $1.77B | $1.37B | $1.55B | $1.27B |
| Income Tax | $1.0M | $300,000 | $13.8M | $28.4M | $37.4M | $41.8M | $36.8M | $35.5M | $75.3M | $50.2M | $46.9M | $97.9M | $123.6M | $332.9M | $127.5M | $168.4M | $451.3M | $39.2M | $119.6M | $93.3M | $198.9M | $245.5M | $152.4M | $152.1M | $216.9M |
| Net Income | -$12.0M | $55.7M | $79.0M | $1.7M | $79.3M | $130.5M | $113.0M | $128.9M | $229.1M | $218.0M | $236.7M | $293.2M | $391.7M | $811.1M | $494.9M | $569.5M | $622.1M | $722.2M | $1.05B | $823.4M | $1.50B | $1.52B | $1.40B | $4.17B | $1.07B |
| EPS | -$0.02 | $0.08 | $0.11 | $0.00 | $0.11 | $0.19 | $0.16 | $0.19 | $0.34 | $0.32 | $0.35 | $0.43 | $0.59 | $1.27 | $0.77 | $0.89 | $0.98 | $1.15 | $1.68 | $1.32 | $2.41 | $2.46 | $2.31 | $6.98 | $1.84 |
| EPS (Diluted) | -$0.02 | $0.08 | $0.11 | $0.00 | $0.11 | $0.18 | $0.16 | $0.18 | $0.33 | $0.31 | $0.33 | $0.41 | $0.57 | $1.25 | $0.75 | $0.87 | $0.96 | $1.13 | $1.64 | $1.30 | $2.38 | $2.44 | $2.30 | $6.97 | $1.83 |
| Shares Outstanding (Diluted) | 706.8 M | 735.6 M | 733.2 M | 744.0 M | 747.6 M | 766.8 M | 752.4 M | 715.2 M | 704.4 M | 715.2 M | 716.4 M | 709.8 M | 682.8 M | 651.0 M | 660.9 M | 653.4 M | 647.7 M | 640.8 M | 636.6 M | 631.9 M | 631.2 M | 624.2 M | 609.4 M | 599.3 M | 585.8 M |
Price
| Price | $93.26 (closing price, November 2, 2026) |
| Market Cap | $53.8B |
| Exchange | NYSE |
| Country | US |
Related companies: ISRG · LIVN · PEN · ABT · MDT · 0Y6X.L · SYK · 0R2S.L
Explore sector: Healthcare · Medical - Devices
More sections of EW: Overview · Financials · Valuation · Statistics · Technical · Ownership · News · Events
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Companies that pass the Buffett method · Companies that pass the Lynch method · Stocks that pass Graham's defensive investor test today · Investment Academy — learn to analyze stocks